Compositions and methods for inhibiting metastasis

• US 20030138429A1
• Filed: 05/22/2002
• Published: 07/24/2003
• Est. Priority Date: 05/22/2001
• Status: Abandoned Application

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Pizzo, Salvatore V., Gonzalez-Gronow, Mario
• Application Number:
  US10/153,428
• Publication Number:
  US 20030138429A1
• Time in Patent Office: Days
• US Class Current: 424/155.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/40 against enzymes

Abstract

Compounds, compositions and methods for inhibiting metastasis, and screening methods for identifying compounds are disclosed. The compounds bind to CD26 and/or plasminogen, and when so bound, inhibit the Ca⁺² signaling cascade that results in the formation of MMP-9. When the compounds directly bind to CD26 in a manner that inhibits the signaling cascade, they inhibit metastasis. When the compounds enhance the ability of angiostatin to bind to CD26 and inhibit the signaling cascade, they are angiostatin allosteric promoters. The compounds can also bind to CD26 in a manner which inhibits the binding of ADA to CD26/DPP IV, and such compounds used in methods for inhibiting deamination of adenosine. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies. The compounds can be conjugated to or combined with various cytotoxic agents and/or labeled compounds. Methods for inhibiting tumor metastasis can be used to treat patients suffering from such tumors.

Claims

1. A composition for use in inhibiting metastasis comprising:

a) a CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter, and

b) a suitable carrier.

2. The composition of claim 1, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter are selected from the group consisting of antibodies, antibody fragments, enzymes, peptides and oligonucleotides.

3. The composition of claim 1, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is a conjugate of an anti-tumor agent that does not bind to CD26 or plasminogen and a compound that does bind to CD26 or plasminogen.

4. The composition of claim 1, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is an antibody or an antibody fragment.

5. The composition of claim 4, wherein the antibody is a monoclonal antibody or antibody fragment thereof.

6. The composition of claim 4, wherein the antibody is a humanized antibody or antibody fragment thereof.

7. The composition of claim 1, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter are present in or conjugated onto a liposome or microparticle that is of a suitable size for intraveneous administration but that lodges in capillary beds.

8. The composition of claim 1, further comprising an anti-tumor agent that does not bind to CD26 or plasminogen.

9. The composition of claim 1, further comprising an anti-angiogenesis agent.

10. A method of inhibiting tumor metastasis, comprising administering to a patient in need of treatment thereof an effective, metastasis inhibiting amount of a CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter.

11. The method of claim 10, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is a compound selected from the group consisting of antibodies, antibody fragments, enzymes, peptides and oligonucleotides.

12. The method of claim 10, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is a conjugate of an anti-tumor agent that does not bind to CD26 and a CD26 antagonist and/or angiostatin allosteric promoter.

13. The method of claim 10, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is an antibody or an antibody fragment.

14. The method of claim 13, wherein the antibody is a monoclonal antibody or antibody fragment thereof.

15. The method of claim 13, wherein the antibody is a humanized antibody or antibody fragment thereof.

16. The method of claim 10, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter are present in or conjugated onto a liposome or microparticle that is of a suitable size for intraveneous administration but that lodges in capillary beds.

17. The method of claim 10, further comprising administering an anti-tumor agent that does not bind to CD26 or plasminogen.

18. The method of claim 11, wherein the CD26 antagonist, plasminogen antagonist, ADA antagonist and/or angiostatin allosteric promoter is administered intravenously, intramuscularly, intradermally or subcutaneously.

19. A method of screening a test compound for its ability to inhibit metastasis comprising:

i) contacting the test compound with CD26 under conditions such that angiostatin would bind to the CD26 in the absence of the test compound, and

ii) determining the binding affinity of the compound to CD26.

20. The method of claim 19 wherein the compound bears a detectable label.

21. The method of claim 19 wherein the CD26 is attached to a solid support.

22. The method of claim 19 wherein the CD26 is associated with a lipid membrane.

23. The method of claim 22 wherein the membrane is a membrane of an intact cell.

24. The method of claim 23 wherein the cell naturally expresses CD26.

25. The method of claim 23 wherein the cell has been transformed with one or more nucleic acid sequence that encode CD26.

26. A compound identified in the method of claim 19 as inhibiting metastasis.

27. A compound identified in the method of claim 19 as enhancing the binding of angiostatin to CD26.

28. A method of screening a test compound for its ability to inhibit metastasis comprising:

i) contacting the test compound with a cell that expresses CD26 under conditions such that angiostatin would bind to the CD26 in the absence of the test compound and under conditions such that the Ca⁺² signaling cascade that results in formation of MMP-9 would otherwise occur,

ii) determining the amount of MMP-9 formed after the compound is contacted with the CD26, and

iii) comparing the amount of MMP-9 formed with a baseline amount of MMP-9 formed when no test compound is added.

29. A CD26 antagonist identified in accordance with the method of claim 28.

30. A monoclonal antibody or antibody fragment thereof specific for CD26 that functions as an CD26 antagonist.

31. A monoclonal antibody or antibody fragment thereof that functions as an angiostatin allosteric promoter.

32. A monoclonal antibody or antibody fragment thereof that functions as a plasminogen antagonist.

33. A monoclonal antibody or antibody fragment thereof that functions as an ADA antagonist.